Abstract:484 Objectives: The Sphingosine-1-phosphate receptor 1 (S1PR1) plays an important role in immune-mediated diseases, such as multiple sclerosis (MS), colitis, influenza, rheumatoid arthritis, inflammatory bowel disease, and atherosclerosis. A suitable S1PR1 PET radiotracer will be very efficient for investigating the changes of S1PR1 in vivo for relative diseases. Based on our previous effort for the development of S1PR1 specific compounds, we recently have synthesized more than 50 new compounds, among which several compounds exhibited high S1PR1 binding potency. One of the most potent S1PR1 compounds was further radiosynthesized with F-18 for in vivo evaluation in rodents and nonhuman primates, to explore its potential to be a suitable S1PR1 PET radiotracer. Methods: A library of fluorine-containing S1PR1 specific compounds were synthesized and screened the in vitro binding potency assay. Using radioactive competitively radioactive assay in which different concentrations of each compound was used to compete with [32P]S1P binding with S1P receptor cell membrane. The precursor for F-18 labeling was also synthesized, and F-18 labeling radiosynthesis was carried out by employing a two-step one-pot procedure, incorporating the F-18 isotope and removal of the protection group. The final product was purified by reverse phase semi-preparative HPLC. The biodistribution study was conducted in adult male SD rats to determine the in vivo tracer distribution. Animals were euthanized at 5, 30, 60 min, and 120 min post injection of [18F]TZ67138. Tissues of interest were collected, weighed, and counted on an automated gamma counter. Uptake of radioactivity was calculated as percentage injected dose per gram (%I.D./g). Dynamic microPET study was performed on a male cynomolgus monkey (~10 kg) using a Focus 220 MicroPET scanner. Results: Five of the library ligands possessed good binding potency, with IC50 95%), as well as high specific activity (> 1.0 Ci/µmol, decay corrected to EOS). The biodistribution study in rats revealed that [18F]TZ67138had a rat brain uptake (%ID/gram) of 0.41 at 5 min, 0.21 at 30 min and 0.16 at 60 min. Similarly, the dynamic microPET scan of nonhuman primates showed that this tracer has good washout kinetics from the brain. The biodistribution study in rats indicated that [18F]TZ67138had good brain uptake (%ID/gram) up to 0.41 at 5 min. No defluroation was observed as the bone uptake was not increased from 5 to 120 min. Nonhuman primate microPET also demonstrated its ability to penetrate into the brain, with the mean SUV value of ~1.2. Conclusions: A series of new S1PR1 specific compounds were designed and synthesized. The in vitro binding affinity assay identified five of these compounds exhibited high binding potency towards S1PR1 (IC50

Indole-propionic acid derivatives as potent, S1P 3-sparing and EAE efficacious sphingosine-1-phosphate 1 (S1P 1) receptor agonists

Discovery of Thiadiazole Amides As Potent, S1p(3)-Sparing Agonists of Sphingosine-1-Phosphate 1 (s1p(1)) Receptor

Design,Synthesis and Biological Evaluation of Potent and Selective S1PR1 Agonists for the Treatment of Ulcerative Colitis

Discovery of Novel N,N-3-phenyl-3-benzylaminopropionanilides As Potent Inhibitors of Cholesteryl Ester Transfer Protein in Vivo.

Discovery of Novel 1,2,4-Thiadiazole Derivatives As Potent, Orally Active Agonists of Sphingosine 1-Phosphate Receptor Subtype 1 (S1P(1)).

Identification of benzoxazole analogs as novel, S1P3 sparing S1P1 agonists

Discovery of 4-Benzyloxybenzo[d]isoxazole-3-amine Derivatives As Highly Selective and Orally Efficacious Human Sphingomyelin Synthase 2 Inhibitors That Reduce Chronic Inflammation in Db/db Mice

Amidoalkylindoles as Potent and Selective Cannabinoid Type 2 Receptor Agonists with in Vivo Efficacy in a Mouse Model of Multiple Sclerosis.

3-Amino-4-(3-hexylphenylamino)-4-oxobutyl Phosphonic Acid (W146), a Selective Antagonist of Sphingosine-1-phospahte Receptor Subtype 1, Enhances AMD3100-stimulated Mobilization of Hematopoietic Stem Progenitor Cells in Animals.

Isoquinolone derivatives as lysophosphatidic acid receptor 5 (LPA5) antagonists: Investigation of structure-activity relationships, ADME properties and analgesic effects

Discovery of N-cyclobutylaminoethoxyisoxazole Derivatives As Novel Sigma-1 Receptor Ligands with Neurite Outgrowth Efficacy in Cells

ST-2191, an Anellated Bismorpholino Derivative of Oxy-Fingolimod, Shows Selective S1P1 Agonist and Functional Antagonist Potency In Vitro and In Vivo

High-affinity σ1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis

Sphingosine 1-phosphate receptor-1 specific agonist SEW2871 ameliorates ANIT-induced dysregulation of bile acid homeostasis in mice plasma and liver

Discovery of (S)-3-(4-(benzyloxy)phenyl)-2-(2-phenoxyacetamido)propanoic Acid Derivatives As a New Class of GPR34 Antagonists.

Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases

Design, Synthesis, and Biological Evaluation of Novel Dual Inhibitors of Secretory Phospholipase A2 and Sphingomyelin Synthase

3D-QSAR Studies on Thiazolidin-4-one S1P1 Receptor Agonists by CoMFA and CoMSIA

Design, Synthesis, and Biological Evaluations of 5-Aryl-pyrazole-3-carboxamide Derivatives As Selective Cb2 Receptor Agonists for the Treatment of Colitis

Synthesis and Biological Evaluation of σ1 Receptor Ligands Based on Phenyl-1,2,4-oxadiazole Derivatives.

Design, synthesis, and in vitro evaluation of new S1PR1 compounds and in vivo studies of an F-18 labeled radiotracer in rodents and monkeys